Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 9, 2025

Kartoon Studios Announces Exclusive Sneak Peek of “Hundred Acre Woods: Winnie and Friends” at Hollywood’s Iconic TCL Chinese Theatre

View original at globenewswire.com
Kartoon Studios Announces Exclusive Sneak Peek of “Hundred Acre Woods: Winnie and Friends” at Hollywood’s Iconic TCL Chinese Theatre A Defining Moment: A sneak preview of Kartoon Studios’ Anticipated Biggest Launch Ever Positions Kartoon Studios for Growth at the Intersection of High-Value Content and a Global Consumer…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hundred Acre Wood's Winnie & Friends thrives at the highest levels of creative and technical excellence and will become a powerful, enduring asset for both audiences and shareholders

    80% confidence

  • The property has potential to become a billion-dollar global evergreen brand for generations to come

    80% confidence

  • This premiere represents far more than a sneak peek—it is the public unveiling of what we believe will become one of Kartoon Studios' most valuable long-term assets

    80% confidence

  • Kartoon Studios is being positioned for sustained growth and long-term shareholder value

    80% confidence

  • The product line will grow with the program, allowing a new generation of preschoolers to discover the joys to be found exploring this dynamic new Hundred Acre Wood with their friends

    80% confidence

  • A.A. Milne's Winnie-the-Pooh is one of the most beloved characters in the world

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com